WideCells, University of Westminster partner to offer short online courses on stem cell storage and treatment

NewsGuard 100/100 Score

WideCells Group PLC, the healthcare services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment, is pleased to announce that its R&D and training development division, WideAcademy, has finalised its syllabus of short courses focused on educating healthcare professionals on the benefits of stem cell storage and treatment. This will provide the Company with a new revenue stream, on commencement of the courses.

The ten short courses are currently being developed alongside the University of Westminster and are anticipated to drive uptake of the Group’s stem cell storage and healthcare services. Jointly overseen by WideCells Group’s Chief Scientific Officer and Dean of WideAcademy, Dr. Peter Hollands, Dr. Emanuela Volpi, Reader in Biomedical Science and Dr. John Murphy, Head of Biomedical Science, both from the University of Westminster, the courses will be delivered by a team of healthcare professionals with a high level of expertise in the field. The collaboration between these parties will ensure the quality of WideAcademy’s educational materials as well academic peer review of course content. The Company anticipates that the first course will commence in early 2017 with the launch of the rest to be staggered over the next 24 months.

In conjunction with this, and in line with its strategy to provide excellence in stem cell education and training, WideAcademy is in the process of developing a conference programme for healthcare and medical professionals. WideAcademy will update the market with further details on the conference, anticipated to be held in Brazil in 2017, once a programme has been finalised. South America's cord blood banking services market has experienced exciting growth in recent years, prompting the Company’s decision to deliver an event in this market.   

WideCells Group CEO, João Andrade, said:

Our stated strategy is to make stem cell treatment affordable and accessible for families worldwide and in turn to fuel innovation and investment into the stem cell industry; we believe that the launch of these short courses will achieve both these goals while also providing the added commercial benefit of increasing uptake of our storage and healthcare services. We look forward to opening up registration to participants.

Our CSO Peter Hollands has an almost unrivalled knowledge of stem cell applications and we are proud to have him on our team. He is passionate about bridging the knowledge gap amongst the healthcare community regarding the rapid advancements in this innovative area of medicine and together with the University of Westminster, a well-respected academic institution, we are ideally positioned to deliver this. We look forward to providing updates regarding the course and our conference in the coming months.

Source: http://www.widecellsgroup.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits